Bad Ad Program for Misleading Drug Ads

 

The U.S. Food and Drug Administration has created a program to help recognize misleading prescription drug promotion and provide an easy way to report concerns.

The program will engage health care providers at medical conventions and partner medical societies to distribute educational materials.

Phases 2 and 3 will expand the FDA’s to update educational materials developed for Phase 1.

The FDA’s traditional monitors prescription drug promotion presentations created by drug companies themselves.

Health care professionals are encouraged to report a potential violation in drug promotion by sending an email to badad@fda.gov or calling 877-RX-DDMAC. Reports can be submitted anonymously.

It is unclear what motivational incentives the FDA can effectively enforce. By signing off on the promotions the FDA actually participates in the promotion of prescription drugs by allowing drug companies and their agents to claim ”FDA approval” as part of promoting the drug to the public and physicians.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm211611.htm

—–

About Author

Leave a Reply